Shiow-Yunn Sheu

Shiow-Yunn Sheu

Auto-generated profile, based on publicly available information

Shiow-Yunn Sheu

Department of Pharmaceutical Sciences, School of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2015 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SSShiow-Yunn Sheu
Shiow-Yunn Sheu
SHShin-Rong Ho
Shin-Rong Ho
Jui-Sheng SunJui-Sheng Sun
Jui-Sheng Sun
CCChing-Yun Chen
Ching-Yun Chen
CKCherng-Jyh Ke
Cherng-Jyh Ke
In osteoarthritis (OA), the imbalance of chondrocytes’ anabolic and catabolic factors can induce cartilage destruction. Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that is capable of inducing chondrocytes and synovial cells to synthesize MMPs. The hypoxia-inducible factor-2alpha (HIF-2alpha, encoded by Epas1) is the catabolic transcription factor in the osteoarthritic process. The purpose of this study is to validate the effects of ecdysteroids (Ecd) on IL-1β- induced cartilage catabolism and the possible role of Ecd in treatment or prevention of early OA. Chondrocytes and articular cartilage was harvested from newborn ICR mice. Ecd effect on chondrocytes viability was tested and the optimal concentration was determined by MTT assay. The effect of HIF-2α (EPAS1) in cartilage catabolism simulated by IL-1β (5 ng/ml) was evaluated by articular cartilage explants culture. The effects of Ecd on IL-1β-induced inflammatory conditions and their related catabolic genes expression were analyzed. Interleukin-1β (IL-1β) treatment on primary mouse articular cartilage explants enhanced their Epas1, matrix metalloproteinases (MMP-3, MMP-13) and ADAMTS-5 genes expression and down-regulated collagen type II (Col2a1) gene expression. With the pre-treatment of 10−8M Ecd, the catabolic effects of IL-1β on articular cartilage were scavenged. In conclusions, Ecd can reduce the IL-1β-induced inflammatory effect of the cartilage. Ecd may suppress IL-1β- induced cartilage catabolism via HIF-2α pathway.

1 February 2010 in Shock
Verified
Journal Article
Closed access
YCYu-Ti Chen
Yu-Ti Chen
STShin-Han Tsai
Shin-Han Tsai
SSShiow-Yunn Sheu
Shiow-Yunn Sheu
LTLi Hsueh Tsai
Li Hsueh Tsai
Ghrelin, an important orexigenic peptide, exerts gastroprokinetic and anti-inflammatory effects. We investigated the role of ghrelin in LPS-induced gastrointestinal (GI) motility disturbances through NO and prostaglandin E2 pathways in mice. Ghrelin-containing cells and its receptor, growth hormone secretagogue receptor 1 (GHSR-1), were localized in the stomach and duodenum using an immunohistochemical method. The distribution of ghrelin-containing cells or GHSR-1 immunoreactivity in both the mucosal and the muscle layers was heterogeneous within both tissues. The i.p. administration of ghrelin (1-20 μg/kg) had no effect on gastric emptying but markedly increased the GI transit (GIT) in normal mice. LPS (20 mg/kg i.p.)-treated mice showed significant decreases in the gastric emptying and GIT. Ghrelin attenuated the LPS-induced delay in gastric emptying and GIT. We also performed immunohistochemical experiments on both tissues. Immunohistochemistry showed the presence of iNOS and cyclooxygenase 2 in both tissues of LPS-treated mice. Treatment of LPS-exposed mice with ghrelin (20 μg/kg) diminished the presence of iNOS but not cyclooxygenase 2 in both tissues. The effect of ghrelin on regulating LPS-induced GI motility disturbance was further found to be associated with a reduction in iNOS expression in the GI tract and plasma NO overproduction rather than regulation of neural or endothelial NO synthase expression in the GI tissue. In addition, ghrelin was found to elevate prostaglandin E2 levels in the GI tissue but showed no significant change in LPS-treated mice. These findings indicate that the action of ghrelin binding to GHSR-1 improves endotoxemia-induced GI motility disturbances mainly through down-regulating the NO pathway in the GI tract.

1 March 2006 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
Jui-Sheng SunJui-Sheng Sun
Jui-Sheng Sun
CWC.-X. Wu
C.-X. Wu
YTY.-H. Tsuang
Y.-H. Tsuang
LCL.-T. Chen
L.-T. Chen
SSS.-Y. Sheu
S.-Y. Sheu

21 November 2006 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
Jui-Sheng SunJui-Sheng Sun
Jui-Sheng Sun
YLYa‐Ying Li
Ya‐Ying Li
MLMan‐Hai Liu
Man‐Hai Liu
SSShiow‐Yunn Sheu
Shiow‐Yunn Sheu

1 October 2012
Verified
Journal Article
Closed access
SSShiow-Yunn Sheu
Shiow-Yunn Sheu
CTChia-Chung Tsai
Chia-Chung Tsai
Jui-Sheng SunJui-Sheng Sun
Jui-Sheng Sun
MCMing-Hong Chen
Ming-Hong Chen
MLMan-Hai Liu
Man-Hai Liu
MSMan-Ger Sun
Man-Ger Sun

16 January 2016 in Molecules
Verified
Journal Article
Open access
PDF file
LCLing-Ling Chiang
Ling-Ling Chiang
ITIng-Jy Tseng
Ing-Jy Tseng
PLPen-Yuan Lin
Pen-Yuan Lin
SSShiow-Yunn Sheu
Shiow-Yunn Sheu
CLChing-Tung Lin
Ching-Tung Lin
MLMei-Hsiang Lin
Mei-Hsiang Lin
The cantharidinimide derivatives, 5a–h, including sulfanilamides containing pyrimidyl, pyrazinyl, hydrogen, thiazolyl, and oxazolyl groups were synthesized. Modification of cantharidinimide by means of the reaction of activated aziridine ring opening led to the discovery of a novel class of antitumor compounds. The analogues 10i–k, 11l–n, 12o–p, and 16q–s were obtained from treating cantharidinimide 6 and analogues (7, 8, and 13) with activated aziridines, which produced a series of ring-opened products including normal and abnormal types. Some of these compounds showed cytotoxic effects in vitro against HL-60, Hep3B, MCF7, and MDA-MB-231 cancer cells. The most potent cytostatic compound, N-cantharidinimido-sulfamethazine (5a), exhibited anti-HL-60 and anti-Hep3B cell activities. Two compounds 5g and 5h displayed slight effects on the Hep3B cell line, while the other compounds produced no response in these four cell lines.